|By PR Newswire||
|April 9, 2014 06:28 AM EDT||
NEW YORK, April 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022
The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.
For the treatment of CD, Indian physicians rely heavily on non-pharmacological methods, such as dietary recommendations, and for pharmacologic therapy, they use generic products within the corticosteroids and 5-ASAs. GlobalData's physician survey showed that these drugs are the mainstay of treatment for mild to moderate CD in India, as well as at earlier lines of therapy for severe disease. While Indian physicians commonly prescribe domestic generics and biosimilars, our primary research revealed that biosimilars were not readily available to those with CD.
- Overview of Crohn's disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in India from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the India Crohn's disease market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Crohn's disease.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of drug performance.
- Obtain sales forecast for drugs from 2012-2022 in India.
1 Table of Contents
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Symptoms 16
3.3 Prognosis 17
3.4 Quality of Life 18
4 Disease Management 19
4.1 Treatment Overview 20
4.2 India 25
4.2.1 Diagnosis 25
4.2.2 Clinical Practice 25
5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 28
5.3 Product Profiles - Major Brands 29
5.3.1 Remicade (infliximab) 29
5.3.2 Other Marketed Products 35
6 Opportunity and Unmet Need 36
6.1 Overview 36
6.2 Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach 37
6.3 More Therapies for Anti-TNF-Refractory Patients 38
6.4 Unmet Needs Gap Analysis 39
6.5 Targeted Therapies 40
6.6 Predictive Tools for Early Diagnosis and Treatment 41
7 Pipeline Assessment 42
7.1 Overview 42
7.2 Promising Drugs in Clinical Development 42
7.3 Other Late-Stage Pipeline Products 44
7.3.1 Cx601 44
7.3.2 RHB-104 (clarithromycin + clofazimine + rifabutin) 46
8 Market Outlook 51
8.1 Global Markets 51
8.1.1 Drivers and Barriers - Global Issues 51
9 India 56
9.1 Forecast 56
9.2 Key Events 58
9.3 Drivers and Barriers 59
9.3.1 Driver: Continued investment in the national healthcare system and services 59
9.3.2 Driver: Sizeable CD patient population that will increase over the coming decade 59
9.3.3 Barrier: Loose intellectual property policies present a major challenge for developers with novel drugs 60
9.3.4 Barrier: Limited access to and the high price point of CD therapies, coupled with many Indians' belief in traditional medicine, negatively impacts branded drug sales 60
9.3.5 Barrier: Downward pricing pressure limits drug sales growth 61
10 Appendix 62
10.1 Bibliography 62
10.2 Abbreviations 67
10.3 Methodology 71
10.4 Forecasting Methodology 71
10.4.1 Diagnosed CD Patients 71
10.4.2 Percent Drug-Treated Patients 72
10.4.3 Drugs Included in Each Therapeutic Class 72
10.4.4 General Pricing Assumptions 72
10.4.5 Individual Drug Assumptions 74
10.4.6 Generic Erosion 74
10.5 Physicians and Specialists Included in This Study 75
10.6 Primary Research - Prescriber Survey 76
10.7 About the Authors 77
10.7.1 Author/Reviewer 77
10.7.2 Global Head of Healthcare 77
10.8 About GlobalData 78
10.9 Disclaimer 78
1.1 List of Tables
Table 1: Symptoms of CD 17
Table 2: Treatment Guidelines for CD 21
Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013 23
Table 4: Leading Branded Drugs Used to Treat CD 29
Table 5: Product Profile - Remicade 31
Table 6: Remicade SWOT Analysis, 2013 34
Table 7: Summary of the Minor Therapeutic Classes in CD, 2013 35
Table 8: Overall Unmet Needs in CD - Current Level of Attainment 37
Table 9: Clinical Unmet Needs in CD - Gap Analysis, 2013 40
Table 10: Promising Drugs in Clinical Development for CD - Pipeline Phase, 2013 42
Table 11: Comparison of Therapeutic Classes in Development for CD, 2013 43
Table 12: Product Profile - Cx601 45
Table 13: Cx601 SWOT Analysis, 2013 46
Table 14: Product Profile - RHB-104 48
Table 15: RHB-104 SWOT Analysis, 2013 50
Table 16: Global CD Market - Drivers and Barriers, 2012-2022 51
Table 17: Sales Forecasts ($) for CD in India, 2012-2022 57
Table 18: Key Events Impacting Sales for CD in India, 2012-2022 58
Table 19: CD Market in India - Drivers and Barriers, 2012-2022 59
Table 20: Physicians Surveyed, By Country 76
1.2 List of Figures
Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right) 13
Figure 2: Potential Biologic Drug Targets for CD 16
Figure 3: Patient Care Path for CD 22
Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in CD, 2012-2022 43
Figure 5: Sales for CD in India by Drug Class, 2012-2022 58
To order this report: PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
Imagine having the ability to leverage all of your current technology and to be able to compose it into one resource pool. Now imagine, as your business grows, not having to deploy a complete new appliance to scale your infrastructure. Also imagine a true multi-cloud capability that allows live migration without any modification between cloud environments regardless of whether that cloud is your private cloud or your public AWS, Azure or Google instance. Now think of a world that is not locked i...
Mar. 29, 2017 03:15 PM EDT Reads: 645
Technology innovation is the driving force behind modern business and enterprises must respond by increasing the speed and efficiency of software delivery. The challenge is that existing enterprise applications are expensive to develop and difficult to modernize. This often results in what Gartner calls "Bimodal IT," where business struggle to apply modern tools and practices to traditional monolithic applications. But these existing assets can be modernized and made more efficient without havin...
Mar. 29, 2017 03:15 PM EDT Reads: 2,630
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost...
Mar. 29, 2017 03:15 PM EDT Reads: 235
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Mar. 29, 2017 03:15 PM EDT Reads: 2,206
SYS-CON Events announced today that Auditwerx will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Auditwerx specializes in SOC 1, SOC 2, and SOC 3 attestation services throughout the U.S. and Canada. As a division of Carr, Riggs & Ingram (CRI), one of the top 20 largest CPA firms nationally, you can expect the resources, skills, and experience of a much larger firm combined with the accessibility and attent...
Mar. 29, 2017 02:30 PM EDT Reads: 654
SYS-CON Events announced today that Technologic Systems Inc., an embedded systems solutions company, will exhibit at SYS-CON's @ThingsExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Technologic Systems is an embedded systems company with headquarters in Fountain Hills, Arizona. They have been in business for 32 years, helping more than 8,000 OEM customers and building over a hundred COTS products that have never been discontinued. Technologic Systems’ pr...
Mar. 29, 2017 02:30 PM EDT Reads: 3,799
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
Mar. 29, 2017 02:30 PM EDT Reads: 2,266
SYS-CON Events announced today that HTBase will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. HTBase (Gartner 2016 Cool Vendor) delivers a Composable IT infrastructure solution architected for agility and increased efficiency. It turns compute, storage, and fabric into fluid pools of resources that are easily composed and re-composed to meet each application’s needs. With HTBase, companies can quickly prov...
Mar. 29, 2017 02:15 PM EDT Reads: 3,242
What if you could build a web application that could support true web-scale traffic without having to ever provision or manage a single server? Sounds magical, and it is! In his session at 20th Cloud Expo, Chris Munns, Senior Developer Advocate for Serverless Applications at Amazon Web Services, will show how to build a serverless website that scales automatically using services like AWS Lambda, Amazon API Gateway, and Amazon S3. We will review several frameworks that can help you build serverle...
Mar. 29, 2017 01:30 PM EDT Reads: 2,243
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...
Mar. 29, 2017 01:30 PM EDT Reads: 1,736
In his session at Cloud Expo, Alan Winters, an entertainment executive/TV producer turned serial entrepreneur, will present a success story of an entrepreneur who has both suffered through and benefited from offshore development across multiple businesses: The smart choice, or how to select the right offshore development partner Warning signs, or how to minimize chances of making the wrong choice Collaboration, or how to establish the most effective work processes Budget control, or how to max...
Mar. 29, 2017 01:30 PM EDT Reads: 534
MongoDB Atlas leverages VPC peering for AWS, a service that allows multiple VPC networks to interact. This includes VPCs that belong to other AWS account holders. By performing cross account VPC peering, users ensure networks that host and communicate their data are secure. In his session at 20th Cloud Expo, Jay Gordon, a Developer Advocate at MongoDB, will explain how to properly architect your VPC using existing AWS tools and then peer with your MongoDB Atlas cluster. He'll discuss the secur...
Mar. 29, 2017 12:45 PM EDT Reads: 713
Buzzword alert: Microservices and IoT at a DevOps conference? What could possibly go wrong? In this Power Panel at DevOps Summit, moderated by Jason Bloomberg, the leading expert on architecting agility for the enterprise and president of Intellyx, panelists peeled away the buzz and discuss the important architectural principles behind implementing IoT solutions for the enterprise. As remote IoT devices and sensors become increasingly intelligent, they become part of our distributed cloud enviro...
Mar. 29, 2017 12:15 PM EDT Reads: 7,894
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
Mar. 29, 2017 11:45 AM EDT Reads: 2,572
SYS-CON Events announced today that Infranics will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Since 2000, Infranics has developed SysMaster Suite, which is required for the stable and efficient management of ICT infrastructure. The ICT management solution developed and provided by Infranics continues to add intelligence to the ICT infrastructure through the IMC (Infra Management Cycle) based on mathemat...
Mar. 29, 2017 11:00 AM EDT Reads: 3,433